Company Filing History:
Years Active: 2017-2021
Title: Yu Bin Choi: Innovator in Antibody Expression Technologies
Introduction
Yu Bin Choi is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of innovative methods for antibody expression. With a total of 3 patents to his name, Choi's work has the potential to advance therapeutic applications in medicine.
Latest Patents
Choi's latest patents include a bicistronic expression vector for antibody expression and a method for producing antibodies using this vector. This invention relates to a bicistronic expression vector that includes a first expression cassette with 'promoter-UTR-intron-antibody light chain gene-polyA' and a second expression cassette with 'promoter-UTR-intron-antibody heavy chain gene-internal ribosome entry site (IRES)-amplification gene-polyA'. This innovative expression vector allows for the efficient production of desired antibodies by culturing transfected animal cells with stability and high efficiency. Another notable patent is for a dual-targeting protein that specifically binds to delta-like ligand 4 (DLL4) and vascular endothelial cell growth factor (VEGF). This novel protein has significant implications for targeted therapies in cancer treatment.
Career Highlights
Throughout his career, Yu Bin Choi has worked with several notable companies, including Abl Bio Inc. and Prestige Biopharma Pte. Ltd. His experience in these organizations has contributed to his expertise in antibody development and biopharmaceutical innovations.
Collaborations
Choi has collaborated with esteemed colleagues such as Dong Heon Lee and Kyung Duk Moon. These partnerships have fostered a collaborative environment that enhances research and development in the field of biotechnology.
Conclusion
Yu Bin Choi is a distinguished inventor whose work in antibody expression technologies is paving the way for advancements in medical therapies. His innovative patents and collaborations reflect his commitment to improving biopharmaceutical applications.